HOUSTON--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News) announces that Neusoft Positron Medical Systems, Shenyang China, has begun preparations for FDA 510k submission on the new AttriusTM PET camera by contracting global regulatory expert TUV (http://www.tuv.com) to help successfully complete the submission. Neusoft Positron Medical Systems has partnered with TUV as a means of insuring success on regulatory affairs on all products including the new AttriusTM PET camera. Neusoft Medical Systems, Positron’s joint venture partner, has a long history with TUV that includes multiple successful 510k submissions to the FDA.
Positron Corporation’s President, Joseph Oliverio stated, “We are pleased to take this next critical step in the execution of Positron’s global business strategy. We are looking forward to receiving our 510k approval as soon as possible and serve the current and future PET market demand.”
About Positron
Positron Corporation designs, manufactures, markets and supports advanced cardiac molecular imaging devices utilizing single photon emission computed tomography (SPECT) and positron emission tomography (PET). The company’s molecular imaging systems incorporate patented and proprietary software and hardware technology for the diagnosis and treatment of patients with heart disease. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. Additional information may be found at http://www.positron.com and http://www.is2medical.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
No comments:
Post a Comment